American Vanguard (AVD) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Net sales rose 7% year-over-year to $124 million in Q1 2026, led by strong U.S. crop and specialty product growth, while international sales declined 7% due to timing issues in Brazil and India.
Gross margin expanded by 500 basis points to 31%, reflecting favorable product mix and operational efficiency.
Adjusted EBITDA surged 245% to $10.3 million, driven by higher-margin product sales and improved cost structure.
Net loss narrowed to $4.1 million ($0.14 per share) from $8.5 million ($0.30 per share) in Q1 2025.
Strategic actions included manufacturing optimization, leadership changes, and a new capital structure to support long-term growth.
Financial highlights
Net sales increased to $124 million from $116 million in Q1 2025, a 7% rise year-over-year.
Adjusted EBITDA reached $10.3 million, up from $3 million, reflecting a 245% increase.
Gross profit rose 27% to $38.4 million, with gross margin improving to 31% from 26% year-over-year.
Cash at quarter-end was $71 million, up from $12 million a year ago, mainly due to debt restructuring.
Net debt increased to $196 million, up from $154 million, primarily due to new term loans and lower customer prepayments.
Outlook and guidance
Full-year 2026 guidance reaffirmed: sales of $530–$550 million and adjusted EBITDA of $44–$48 million.
Targeting over $600 million in annualized revenue by 2028, with a long-term goal of double-digit EBITDA margins and a net leverage ratio of 3.0x.
Plans to launch 50 new products over five years, aiming for $100 million in annualized revenue by 2030.
Focused on reducing net debt, improving free cash flow, and strengthening the balance sheet over the next two years.
Management expects all remaining customer prepayments to be recognized as revenue in fiscal 2026.
Latest events from American Vanguard
- 2025 margins and EBITDA held steady despite lower sales; 2026 targets growth and improved profitability.AVD
Q4 20253 May 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance focus.AVD
Proxy filing23 Apr 2026 - Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 20242 Feb 2026 - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 202415 Jan 2026 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025 - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 202424 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing2 Dec 2025 - Adjusted EBITDA up 350%, gross margin 29%, and net loss narrowed on strong U.S. crop sales.AVD
Q3 202517 Nov 2025 - Q1 sales dropped 14% with a net loss, but cost cuts and lower debt support recovery.AVD
Q1 202514 Nov 2025